参考文献: [1] NCCN Guidelines Version 1.2023 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. [2] Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, ...
参考文献: [1]NCCN CLL/SLL Guidelines 2024 V1. [2]CSCO淋巴瘤指南2023. [3]Jeff P. Sharman, et al. 2023 ASH. Abstract 636. [4]Kohrt H E, et al. Blood, 2014, 123(12): 1957. [5]Golay J, et al. Haematol...
随着本次在中国的多个重磅获批,泽布替尼已成为中国唯一获批用于CLL/SLL和WM一线治疗的新一代BTK抑制剂,将为中国临床医生提供新的标准治疗方案,从而支持患者迎来更长生存和更好的生活质量。” 此前,泽布替尼已于2023年1月获得美国食品药物监督管理局(FDA)批准,用于治疗CLL/SLL成人患者,并于2022年9月获得英国国家卫...
[1] Jeff Porter Sharman, et al. 2022ASCO.Abstract#7539. [2] Wojciech Jurczak, et al. 2022ASCO.Abstract#7538. [3] NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines®)for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 2022 Version 3. [4] 程诗佳,等.慢性淋巴细胞白血病治疗...
1.NCCN Guidelines Version 1.2023 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 2.Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results...
[9] Annals of Oncology, Marginal Zone Lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, January 6, 2020.[10] Cerhan, J.R. and T.M. Habermann, Epidemiology of Marginal Zone Lymphoma. Ann Lymphoma, 2021.[11] Smith, A., et al., Lymphoma incidence, ...
2022;107(6):1335-1346. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma V.1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed November 21, 2024. ...
此前,泽布替尼已于2023年1月获得美国食品药物监督管理局(FDA)批准,用于治疗CLL/SLL成人患者,并于2022年9月获得英国国家卫生与临床优化研究所(NICE)推荐成为英格兰和威尔士地区首个也是唯一一个被推荐用于治疗WM的常规药物。 百济神州总裁、首席运营官兼中国区总经理吴晓滨博士表示:“百济神州深刻理解中国肿瘤患者对国际...
[9] Annals of Oncology, Marginal Zone Lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, January 6, 2020. [10] Cerhan, J.R. and T.M. Habermann, Epidemiology of Marginal Zone Lymphoma. Ann Lymphoma, 2021. ...
Currently asymptomatic, she undergoes surveillance with hematology and nephrology, off venetoclax per guidelines, with monthly labs and quarterly flow cytometry monitoring, alongside avoidance of nephrotoxic medications and ensuring hydration. Resumption of therapy is considered if renal function deteriorates ...